Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalised viral vector-based cancer vaccines, has raised €67.5 million in an oversubscribed Series C financing round.
The proceeds will enable Nouscom to advance its pipeline and complete Phase II clinical trials with its cancer vaccine NOUS-209.
Representatives from Andera Partners, Bpifrance and M Ventures, who led the financing, have joined the Nouscom Board of Directors.
Dr Marina Udier, Chief Executive Officer of Nouscom, said: “This oversubscribed financing, in what is a challenging environment for all biotech companies, is testament to the faith that new and existing investors place in Nouscom and our best-in-class technology. This financing will allow us to further accelerate development across our wholly owned clinical portfolio reporting multiple clinical trial readouts including from our ongoing randomised Phase II clinical trial with NOUS-209.”
The company is also continuing with an ongoing Phase Ib study and advancement of NOUS-209 monotherapy in Lynch Syndrome (LS) carriers, investigating the potential to intercept, prevent or delay cancer before it occurs. LS carriers have a genetic predisposition to and consequently higher risk of developing certain cancers.
Promising initial results from this study were reported at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting.
In addition, Nouscom plans to complete a Phase Ib study evaluating NOUS-PEV, a personalised cancer immunotherapy, in combination with a checkpoint inhibitor in patients with advanced melanoma.
